Heartflow, Inc.
Heartflow, Inc. (Nasdaq: FLOW) operates as a software and artificial intelligence company focused on transforming the diagnosis and management of coronary artery disease, a leading cause of death worldwide. The company's website is www.heartflow.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Heartflow, Inc. does
In the company’s own words
Heartflow, Inc. (Nasdaq: FLOW) operates as a software and artificial intelligence company focused on transforming the diagnosis and management of coronary artery disease, a leading cause of death worldwide. The company's website is www.heartflow.com.
The company provides the Heartflow Platform, an AI-powered diagnostic solution that enhances coronary computed tomography angiography (CCTA) imaging by applying advanced computational fluid dynamics and deep learning algorithms to create personalized three-dimensional models of patients' hearts. This technology delivers actionable insights on blood flow, stenosis, plaque volume, and plaque composition, enabling more accurate non-invasive diagnosis compared to traditional imaging methods.
Heartflow's product portfolio consists of three commercially available offerings and one product expected to launch in the second quarter of 2026. Heartflow FFRCT Analysis, the company's flagship product, represents 98 percent of total revenue and calculates blood flow to identify clinically significant coronary artery disease. Heartflow RoadMap Analysis provides anatomical visualization to improve CCTA interpretation efficiency and consistency. Heartflow Plaque Analysis automatically assesses coronary plaque characteristics and volumes to optimize medical treatment strategies. The forthcoming Heartflow PCI Navigator will provide pre-procedure assessment for interventional cardiologists.
As of December 31, 2025, the Heartflow Platform had been used to assess coronary artery disease in more than 600,000 patients, including 219,000 in 2025 alone. The company operates more than 1,465 accounts across the United States. The platform has been validated through over 200 clinical studies involving more than 365,000 patients, with results published in over 600 peer-reviewed publications.
Heartflow generates revenue on a pay-per-click basis, with customers billed each time physicians access Heartflow FFRCT Analysis or Heartflow Plaque Analysis. Both products have received FDA clearance and established Category I Current Procedural Terminology codes, with reimbursement coverage representing approximately 99 percent of covered lives for FFRCT Analysis and 75 percent for Plaque Analysis. The company employs a direct sales organization combining Territory Sales Managers focused on new account acquisition with Territory Account Managers driving utilization expansion at existing accounts.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1464521
- SIC
- 3841
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Heartflow, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Heartflow, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Heartflow, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Heartflow, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Heartflow, Inc.'s last four quarterly filings that the numbers alone won't show?”